Clinical trials: Relapsed Leukemia
Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL)
GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors
About this study This is the first study of VTRU200 in people. The main purpose of this study is to find a safe dose of VTRU200 and learn how the medicine behaves in the body.
- Conditions
- Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL), High Risk Myelodysplastic Syndrome, Solid Tumor Malignancies
- Trial name
- NCT07749976
- Testing
- VTRU200
- Volunteers
- 108 people
- Sponsor
- Vitruviae
Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes
First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
This First In Human (FIH) study is a prospective, open-label, multicenter, Phase 1 study, with a dose escalation design, followed by an optimized design.
- Trial name
- ODYSSEY (NCT05601726)
- Testing
- ABD-3001
- Where
- 3 sites in France
- Volunteers
- 36 people
- Sponsor
- Advanced BioDesign
Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL)
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Adult patients with Relapsed or Refractory (R/R) Lymphomas, Large Granular Lymphocytic Leukemia (LGL-L)…
- Conditions
- Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L)
- Trial name
- NCT05225584
- Testing
- KT-333
- Where
- 13 sites in United States
- Volunteers
- 56 people
- Sponsor
- Kymera Therapeutics, Inc.
B-precursor Acute Lymphoblastic Leukemia, ALL
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
It is an open-label dose-escalating study in sequential cohorts to assess safety and pharmacokinetics of GNR-084.
- Conditions
- B-precursor Acute Lymphoblastic Leukemia, ALL, GNR-084
- Trial name
- NCT04601584
- Testing
- Cohort 1, GNR-084, Cohort 2, GNR-084, Cohort 3, GNR-084
- Where
- 3 sites in Russia
- Volunteers
- 14 people
- Sponsor
- AO GENERIUM
Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML)
Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia
The purpose of this study is to assess the safety and efficacy of QHRD107 capsule combined with Venclexta and azacitidine in the treatment of relapsed/refractory acute myeloid leukemia: a single-arm, open, multicenter Phase IIa…
- Trial name
- NCT06532058
- Testing
- QHRD107 capsule，Venclexta and Azacitidine
- Where
- 10 sites in China
- Volunteers
- 53 people
- Sponsor
- Changzhou Qianhong Bio-pharma Co., Ltd.
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
An open, multicenter, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics/pharmacokinetics, and antitumor activity of GNC-038 quad-specific antibody injection in relapsed or refractory non-Hodgkin's…
- Trial name
- NCT04606433
- Testing
- GNC-038
- Where
- 10 sites in China
- Volunteers
- 47 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
AML With FLT3 Mutation
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
The purpose of this study was to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated AML who were refractory to or had relapse after first-line AML therapy as shown with…
- Trial name
- NCT03182244
- Testing
- Gilteritinib, Cytarabine, Mitoxantrone
- Where
- 49 sites in China, Malaysia and 3 more
- Volunteers
- 276 people
- Sponsor
- Astellas Pharma Inc
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.
A phase 1/2 study to assess the safety and efficacy of MB-102 in patients with relapsed or refractory BPDCN
- Trial name
- NCT04109482
- Testing
- MB-102, Fludarabine, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- Mustang Bio
Acute Myeloid Leukemia, Myelodysplastic Syndromes
ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML
TCB008-003 (ACHIEVE2) is an open-label, multi-center study conducted in 2 parts (dose escalation followed by dose expansion) to evaluate safety, persistence/expansion, and preliminary efficacy of single and multiple intravenous…
- Trial name
- ACHIEVE2 (NCT06463327)
- Testing
- TCB008
- Volunteers
- 69 people
- Sponsor
- TC Biopharm
Myelodysplastic Syndromes, Myelogenous Leukemia, Acute
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome
This study will assess the safety and efficacy of vismodegib in patients with relapsed/refractory acute myelogenous leukemia (AML) and relapsed/refractory high-risk myelodysplastic syndrome (MDS).
- Trial name
- NCT01880437
- Testing
- cytarabine, vismodegib
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Leukemia
STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
RATIONALE: STI571 may interfere with the growth of cancer cells and may be effective treatment for chronic myelogenous leukemia.
- Trial name
- NCT00006053
- Testing
- imatinib mesylate
- Where
- United States
- Sponsor
- Novartis
Non-hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies
ZX-101A-101 is a Phase 1/2a, first-in-human, open-label, multicenter, multiple-ascending dose study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamic, and preliminary antitumor activity of ZX-101A…
- Conditions
- Non-hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT04504708
- Testing
- ZX-101A
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Hangzhou Zenshine Pharmaceuticals Co., Ltd.
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
The purpose of this single-arm, open-label, Phase 1b/2a, multicenter basket study is to evaluate whether tafasitamab and parsaclisib can be safely combined at the recommended Phase 2 dose (RP2D) and dosing regimen that was…
- Trial name
- topMIND (NCT04809467)
- Testing
- tafasitamab, parsaclisib
- Where
- 50 sites in United States, Austria and 5 more
- Volunteers
- 54 people
- Sponsor
- Incyte Corporation
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescents with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has come back after treatment…
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric Cancer
- Trial name
- NCT07770698
- Testing
- sonrotoclax, Azacitidine, Inotuzumab ozogamicin
- Volunteers
- 30 people
- Sponsor
- BeOne Medicines
Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies
- Conditions
- Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome
- Trial name
- NCT06034275
- Testing
- VIP943 (QW), VIP943 (BIW)
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Vincerx Pharma, Inc.
Acute Myeloid Leukemia
A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms
Phase I, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of HMPL-306 in Patients of Relapsed/Refractory Myeloid Leukemia/Neoplasms with IDH1 and/or IDH2 Mutation.
- Trial name
- NCT04272957
- Testing
- HMPL-306
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Hutchison Medipharma Limited
CD7+ T-ALL/LBL
Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
This is a phase I, open-label, dose-escalation clinical trial. The primary objectives are to assess the safety of PA3-17 injection in pediatric and adolescent participants with relapsed/refractory T-lymphoblastic…
- Trial name
- R/R T-ALL/LBL (NCT07623681)
- Testing
- T cell injection targeting CD7 chimeric antigen receptor
- Where
- China
- Volunteers
- 12 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Acute Myeloid Leukemia
Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia
This is an open label, multicenter Phase 1 study to determine the MTD, dosing schedule and RP2D of IMGN779 when administered as mono-therapy to adult AML patients with CD33 -positive disease.
- Trial name
- NCT02674763
- Testing
- IMGN779
- Where
- 7 sites in United States
- Volunteers
- 62 people
- Sponsor
- ImmunoGen, Inc.
T-cell Acute Lymphoblastic Leukemia, Lymphoblastic T-Cell Lymphoma
Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL
First in humans, exploratory, open-label, single-arm, multicentre, non-competitive, dose escalation study to assess the safety and efficacy of CD1a-CAR T therapy in patients with relapsed/refractory (R/R) T-cell acute…
- Trial name
- CARxALL (NCT05679895)
- Testing
- CD1a-CAR T
- Where
- 2 sites in Spain
- Volunteers
- 20 people
- Sponsor
- OneChain Immunotherapeutics
Chronic Lymphocytic Leukemia
HuMax-CD20 in Chronic Lymphocytic Leukemia
The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Chronic Lymphocytic Leukemia.
- Trial name
- NCT00093314
- Testing
- HuMax-CD20
- Where
- United States
- Sponsor
- GlaxoSmithKline